{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:20:16Z","timestamp":1648588816445},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1007\/s11886-003-0060-x","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T09:49:40Z","timestamp":1180172980000},"page":"259-265","source":"Crossref","is-referenced-by-count":2,"title":["Optimal medical management of angina"],"prefix":"10.1007","volume":"5","author":[{"given":"Brian","family":"Noronha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"60_CR1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/bmj.322.7298.1338","volume":"322","author":"M Moher","year":"2001","unstructured":"Moher M, Yudkin P, Wright L, et al.: Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. Br Med J 2001, 322:1338.","journal-title":"Br Med J"},{"key":"60_CR2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.312.7034.827","volume":"312","author":"North of England Stable Angina Guideline Development Group","year":"1996","unstructured":"North of England Stable Angina Guideline Development Group: North of England evidence based guidelines development project: summary version of evidence based guidelines for the primary care management angina. Br Med J 1996, 312:827\u2013832.","journal-title":"Br Med J"},{"key":"60_CR3","unstructured":"Graves EJ, Kozak LJ: Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996. Vital Health Stat 13 1998:1\u2013151."},{"key":"60_CR4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1161\/01.CIR.98.18.1860","volume":"98","author":"PW Armstrong","year":"1998","unstructured":"Armstrong PW, Fu Y, Chang WC, et al.: Acute coronary syndromes in the GUSTO-2b trial: prognostic insights and impact of recurrent ischemia. Circulation 1998, 98:1860\u20131868.","journal-title":"Circulation"},{"key":"60_CR5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"E Braunwald","year":"2000","unstructured":"Braunwald E, Antman EM, Beasley JW, et al.: ACC guidelines for management of patients with unstable angina and non-ST segment elevation myocardial infarction. J Am Coll Cardiol 2000, 36:970\u20131062.","journal-title":"J Am Coll Cardiol"},{"key":"60_CR6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(01)06585-0","volume":"358","author":"CW Hamm","year":"2001","unstructured":"Hamm CW, Bertrand M, Braunwald E: Acute coronary syndrome without ST segment elevation: implementation of new guidelines: Lancet 2001, 358:1533\u20131538.","journal-title":"Lancet"},{"key":"60_CR7","first-page":"1105","volume-title":"Heart Disease. A Textbook of Cardiovascular Medicine","author":"R Ross","year":"1997","unstructured":"Ross R: The pathogenesis of atherosclerosis. In Heart Disease. A Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:1105\u20131125."},{"key":"60_CR8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.CIR.80.1.198","volume":"80","author":"P Bogaty","year":"1989","unstructured":"Bogaty P, Hackett D, Davies G, Maseri A: Vasoreactivity of the culprit lesion in unstable angina. Circulation 1989, 80:198\u2013205.","journal-title":"Circulation"},{"key":"60_CR9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/01.CIR.73.3.418","volume":"73","author":"M Davies","year":"1986","unstructured":"Davies M, Thomas M, Knapman P, Hangartner R: Intram yocardial platelet aggregation in patients with unstable angina suffering sudden ischaemic death. Circulation 1986, 73:418\u2013427.","journal-title":"Circulation"},{"key":"60_CR10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/hrt.81.5.546","volume":"81","author":"D Bono de","year":"1999","unstructured":"de Bono D: Investigation and management of stable angina; revised guidelines 1998. Heart 1999, 81:546\u2013555.","journal-title":"Heart"},{"key":"60_CR11","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1161\/01.CIR.99.21.2829","volume":"99","author":"RJ Gibbons","year":"1999","unstructured":"Gibbons RJ, Chatterjee K, Daley J, et al.: ACC\/AHA\/ACM-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. (A report of the American College of Cardiology\/American Heart Association Task Force on Practise Guidelines.) Circulation 1999, 99:2829\u20132848.","journal-title":"Circulation"},{"key":"60_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0735-1097(94)00345-Q","volume":"25","author":"T Arnim Von","year":"1995","unstructured":"Von Arnim T: Medical therapy to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS): a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995, 25:231\u2013238.","journal-title":"J Am Coll Cardiol"},{"key":"60_CR13","doi-asserted-by":"crossref","unstructured":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival. Lancet 1986, 2:57\u201366.","DOI":"10.1016\/S0140-6736(86)91607-7"},{"key":"60_CR14","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group: Effects of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001\u20132007.","journal-title":"Lancet"},{"key":"60_CR15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ajh\/5.1.37","volume":"5","author":"S Wassertheil-Smoller","year":"1992","unstructured":"Wassertheil-Smoller S, Oberman A, Blauxfox MD, et al.: The trial of anti-hypertensive Intervention and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk and quality of life. Am J Hypertens 1992, 5:47\u201348.","journal-title":"Am J Hypertens"},{"key":"60_CR16","first-page":"535","volume":"3","author":"S Silber","year":"1990","unstructured":"Silber S: Nitrates: why and how should they be used? Current status of usefulness of nitroglycerin, isosorbide dinitrate, and isosorbide-mononitrate. Eur J Clin Pharm 1990, 3:535\u2013551.","journal-title":"Eur J Clin Pharm"},{"key":"60_CR17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","volume":"92","author":"LH Opie","year":"1995","unstructured":"Opie LH, Messerli FH: Nifedipine and mortality. Grave defects in the dossier. Circulation 1995, 92:1326\u20131331.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"60_CR18","first-page":"301","volume":"40","author":"N Rehnqvist","year":"1995","unstructured":"Rehnqvist N, Hjemdahl P, Billing E, et al.: Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Cardiologia 1995, 40(Suppl 1):301.","journal-title":"Cardiologia"},{"key":"60_CR19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0735-1097(95)00489-0","volume":"27","author":"S Savonitto","year":"1996","unstructured":"Savonitto S, Ardissiono D, Egstrup K, et al.: Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996, 27:311\u2013316.","journal-title":"J Am Coll Cardiol"},{"key":"60_CR20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/0002-9149(90)90320-Z","volume":"65","author":"KR Rice","year":"1990","unstructured":"Rice KR, Gervino E, Jarisch WR, Stone PH: Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina. Am J Cardiol 1990, 65:1097\u20131101.","journal-title":"Am J Cardiol"},{"key":"60_CR21","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","volume":"359","author":"HJ Dargie","year":"2002","unstructured":"Dargie HJ, Ford I, Fox KM, Hillis WS: Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet 2002, 359:1269\u20131275. This study demonstrated a significant mortality benefit with nicorandil therapy, due to a reduction in major coronary events in patients with stable angina.","journal-title":"Lancet"},{"key":"60_CR22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","volume":"340","author":"S Juul-Moller","year":"1992","unstructured":"Juul-Moller S, Edvardsson N, Jahnmatz B, et al.: Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992, 340:1421\u20131425.","journal-title":"Lancet"},{"key":"60_CR23","doi-asserted-by":"crossref","unstructured":"A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996, 348:1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"60_CR24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Danhlof","year":"2002","unstructured":"Danhlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002, 359:995\u20131003.","journal-title":"Lancet"},{"key":"60_CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation Study investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation Study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in patients with diabetes mellitus: Results of the HOPE and MICRO-HOPE sub-study. Lancet 2000, 355:253\u2013259.","journal-title":"Lancet"},{"key":"60_CR26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.97.10.946","volume":"97","author":"AL Gould","year":"1998","unstructured":"Gould AL, Rossouw JE, Santanello NC, et al.: Cholesterol reduction yields clinical benefits: impact of statin trials. Circulation 1998, 97:946\u2013952.","journal-title":"Circulation"},{"key":"60_CR27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.321.7267.983","volume":"321","author":"M Pignone","year":"2000","unstructured":"Pignone M, Phillips C, Mulrow C: Use of lipid lowering drugs for primary prevention of coronary heart disease: a metaanalysis of randomised trials. Br Med J 2000, 321:983\u2013986.","journal-title":"Br Med J"},{"key":"60_CR28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(81)91338-6","volume":"2","author":"I Hjermann","year":"1981","unstructured":"Hjermann I, Velve Byre K, Holme I, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from Oslo study Group of a randomised trial in healthy men. Lancet 1981, 2:1303\u20131310.","journal-title":"Lancet"},{"key":"60_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type-2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229\u2013234.","journal-title":"N Engl J Med"},{"key":"60_CR30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccarao O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434\u2013444.","journal-title":"Diabetes Care"},{"key":"60_CR31","doi-asserted-by":"crossref","unstructured":"Intensive blood glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS-33). Lancet 1998, 352:837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"60_CR32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"384","author":"N Gaede","year":"2003","unstructured":"Gaede N, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 384:383\u2013393.","journal-title":"N Engl J Med"},{"key":"60_CR33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/01.CIR.80.2.410","volume":"80","author":"E Braunwald","year":"1989","unstructured":"Braunwald E: Unstable angina: a classification: Circulation 1989, 80:410\u2013414.","journal-title":"Circulation"},{"key":"60_CR34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jama.1995.03520260058033","volume":"273","author":"JE Calvin","year":"1995","unstructured":"Calvin JE, Klein LW, VandenBerg BJ, et al.: Risk strafication in unstable angina. Prospective validation of the Braunwald classification. JAMA, 1995, 273:136\u2013141.","journal-title":"JAMA"},{"key":"60_CR35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0002-9149(89)90829-1","volume":"64","author":"I Wilcox","year":"1998","unstructured":"Wilcox I, Freedman SB, McCredie RJ, et al.: Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris. Am J Cardiol 1998, 64:845\u2013848.","journal-title":"Am J Cardiol"},{"key":"60_CR36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0735-1097(96)00560-8","volume":"29","author":"G Dangas","year":"1997","unstructured":"Dangas G, Mehran R, Wallestein S, et al.: Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997, 29:519\u2013525.","journal-title":"J Am Coll Cardiol"},{"key":"60_CR37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","volume":"319","author":"P Theraux","year":"1988","unstructured":"Theraux P, Ouimet H, McCans J, et al.: Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988, 319:1105\u20131111.","journal-title":"N Engl J Med"},{"key":"60_CR38","first-page":"494","volume":"345","author":"The CURE investigators","year":"2002","unstructured":"The CURE investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without STsegment elevation. N Engl J Med 2002, 345:494\u2013502. This major trial demonstrated the benefit of additional antiplatelet therapy with clopidogrel in acute coronary syndromes. Treatment with clopidogrel reduced the risk of MI and recurrent ischemia, with a trend toward lower rates of stroke and death from cardiovascular causes.","journal-title":"N Engl J Med"},{"key":"60_CR39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","volume":"339","author":"The PURSUIT trial investigators","year":"1998","unstructured":"The PURSUIT trial investigators: Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT). N Engl J Med 1998, 339:436\u2013443.","journal-title":"N Engl J Med"},{"key":"60_CR40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","volume":"338","author":"The PRISM Study investigators","year":"1998","unstructured":"The PRISM Study investigators: A comparison of aspirin plus tirofiban with aspirin in unstable angina. N Engl J Med 1998, 338:1498\u20131505.","journal-title":"N Engl J Med"},{"key":"60_CR41","doi-asserted-by":"crossref","unstructured":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998, 338:1488\u20131497.","DOI":"10.1056\/NEJM199805213382102"},{"key":"60_CR42","first-page":"1429","volume":"336","author":"The CAPTURE investigators","year":"1997","unstructured":"The CAPTURE investigators: Randomised placebo controlled trial of abxicimab before and during coronary intervention in refractory angina. The CAPTURE study. Lancet 1997, 336:1429\u20131435.","journal-title":"Lancet"},{"key":"60_CR43","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","volume":"97","author":"The PARAGON investigators","year":"1998","unstructured":"The PARAGON investigators: Randomised placebo controlled trial of lamifiban, heparin or both in unstable angina. Circulation 1998, 97:2386\u20132395.","journal-title":"Circulation"},{"key":"60_CR44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","volume":"359","author":"E Boersma","year":"2002","unstructured":"Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein 11b\/111a inhibitors in acute coronary syndrome-A meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189\u2013198.","journal-title":"Lancet"},{"key":"60_CR45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","volume":"276","author":"A Oler","year":"1996","unstructured":"Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with uunstable angina. A meta-analysis. JAMA 1996, 276:811\u2013815.","journal-title":"JAMA"},{"key":"60_CR46","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","volume":"347","author":"FRISC study group","year":"1996","unstructured":"FRISC study group: Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996, 347:561\u2013568.","journal-title":"Lancet"},{"key":"60_CR47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","volume":"20","author":"The FRAXIS study group","year":"1999","unstructured":"The FRAXIS study group: Comparison of two treatment duration (6 days and 14 days) of a low-molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (Fraxiparine in Ischemic Syndrome). Eur Heart J 1999, 20:1553\u20131562.","journal-title":"Eur Heart J"},{"key":"60_CR48","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","volume":"100","author":"EM Antman","year":"1999","unstructured":"Antman EM, McCabe CH, Premmereur J, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina \/ non-Q wave myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) 2b trial. Circulation 1999, 100:1593\u20131601.","journal-title":"Circulation"},{"key":"60_CR49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.11.3838","volume":"96","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low molecular weight heparin with unfractionated heparin in unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96:61\u201368.","journal-title":"Circulation"},{"key":"60_CR50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Denmers C, Gurfinkel EP, et al.: Efficacy and Safety of subcutaneous Enoxaparin in Non-Q wave Coronary Events Study Group (ESSENCE). A comparison of low-molecular weight heparin with unfractionated heparin for coronary artery disease. N Engl J Med 1997, 337:447\u2013452.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-003-0060-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-003-0060-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-003-0060-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:55:56Z","timestamp":1559433356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-003-0060-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["60"],"URL":"https:\/\/doi.org\/10.1007\/s11886-003-0060-x","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}